Skip to search formSkip to main contentSkip to account menu

teprotumumab

Known as: Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I Receptor)(Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer 
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (2)

R 1507RV001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves' disease for which no currently available medical… 
2020
2020
Teprotumumab for Thyroid Eye Disease.
Thyroid eye disease (TED) affects up to 50% of patients with Graves disease (GD) with rare severe visual complications.1 In TED… 
2020
2020
SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
Abstract Introduction: Teprotumumab treatment resulted in statistically and clinically meaningful improvements across multiple… 
2020
2020
OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
Abstract Introduction: Teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody, was recently shown… 
2020
2020
Teprotumumab – selektive IGF-1-Rezeptor-Blockade verbessert signifikant die endokrine Orbitopathie beim Morbus Basedow
Eine endokrine Orbitopathie (EO) ist bei über 50% der Patienten mit Morbus Basedow nachweisbar. Das klinische Bild reicht von… 
2020
2020
[Teprotumumab - selective IGF-1-receptor blockade improves significantly endocrine opthalmopathy in Basedow's disease].
2019
2019
SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
Abstract Objective A multicenter, double-masked, randomized, placebo-controlled, phase two trial of 88 patients with active… 
2018
2018
Considering use of teprotumumab in thyroid eye disease patients
2017
2017
Teprotumumab reduziert endokrine Orbitopathie
Der insulinähnliche Wachstumsfaktor 1 (IGF-1) verstärkt synergistisch die Wirkung des schilddrüsenstimulierenden Hormons. Bei… 
2017
2017
Teprotumumab, an Antibody that Blocks the IGF-I Receptor, Causes Dramatic Improvement in Graves’ Orbitopathy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)